Abstract:In a recent article, Yamagishi et al. demonstrated that treatment with the EZH1/2 inhibitor, valemetostat, disrupts the initially elevated levels of H3K27me3 in Adult T‐cell leukaemia/lymphoma (ATL). This disruption promotes chromatin accessibility and enhances the expression of tumour suppressor genes. However, extended exposure to the inhibitor induces resistance mechanisms, including mutations in PRC2 components and DNA methylation regulators, ultimately leading to reduced sensitivity to the inhibitor and eventual silencing of tumour suppressor genes. Epigenetic modifications, particularly through methylation of DNA packaging histones, play a pivotal role in controlling gene expression. Aberrant patterns of histone methylation have been associated with the development and progression of hematological malignancies. Unraveling the impact of aberrant histone marks on gene expression and leukemogenesis has spurred a concerted effort to develop clinically effective epigenetic therapies. In malignancies associated with the accumulation of histone H3 lysine trimethylation (H3K27me3), one such intervention involves preventing the deposition of this repressive histone mark by inhibiting the histone‐modifying enzymes EZH1 and EZH2. While inhibition of EZH1/2 has demonstrated efficacy in both preclinical studies and clinical trials in various cancers, studies delineating the dynamic effect of EZH1/2 inhibition on H3K27me3 and disease relapse in clinical samples are lacking. In a recent publication, Yamagishi et al. explore how responses of a patient with adult T‐cell leukemia/lymphoma to valemetostat, an EZH1/2 inhibitor, are associated with changes in H3K27me3, chromatin accessibility and gene expression, and how these changes can be circumvented in relapsed disease.

Unlocking adult T‐cell leukemia/lymphoma's epigenetic secrets: delving into the mechanism and impact of EZH1/2 inhibition